Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
Intervalo de ano de publicação
1.
Pediatr Rheumatol Online J ; 15(1): 50, 2017 Jun 13.
Artigo em Inglês | MEDLINE | ID: mdl-28610606

RESUMO

BACKGROUND: The prognosis of children with juvenile dermatomyositis (JDM) has improved remarkably since the 1960's with the use of corticosteroid and immunosuppressive therapy. Yet there remain a minority of children who have refractory disease. Since 2003 the sporadic use of biologics (genetically-engineered proteins that usually are derived from human genes) for inflammatory myositis has been reported. In 2011-2016 we investigated our collective experience of biologics in JDM through the Childhood Arthritis and Rheumatology Research Alliance (CARRA). METHODS: The JDM biologic study group developed a survey on the CARRA member experience using biologics for Juvenile DM utilizing Delphi consensus methods in 2011-2012. The survey was completed online by the CARRA members interested in JDM in 2012. A second survey was similarly developed that provided more opportunity to describe their experiences with biologics in JDM in detail and was completed by CARRA members in Feb 2013. During three CARRA meetings in 2013-2015, nominal group techniques were used for achieving consensus on the current choices of biologic drugs. A final survey was performed at the 2016 CARRA meeting. RESULTS: One hundred and five of a potential 231 pediatric rheumatologists (42%) responded to the first survey in 2012. Thirty-five of 90 had never used a biologic for Juvenile DM at that time. Fifty-five of 91 (denominators vary) had used biologics for JDM in their practice with 32%, 5%, and 4% using rituximab, etanercept, and infliximab, respectively, and 17% having used more than one of the three drugs. Ten percent used a biologic as monotherapy, 19% a biologic in combination with methotrexate (mtx), 52% a biologic in combination with mtx and corticosteroids, 42% a combination of a biologic, mtx, corticosteroids (steroids), and an immunosuppressive drug, and 43% a combination of a biologic, IVIG and mtx. The results of the second survey supported these findings in considerably more detail with multiple combinations of drugs used with biologics and supported the use of rituximab, abatacept, anti-TNFα drugs, and tocilizumab in that order. One hundred percent recommended that CARRA continue studying biologics for JDM. The CARRA meeting survey in 2016 again supported the study and use of these four biologic drug groups. CONCLUSIONS: Our CARRA JDM biologic work group developed and performed three surveys demonstrating that pediatric rheumatologists in North America have been using multiple biologics for refractory JDM in numerous scenarios from 2011 to 2016. These survey results and our consensus meetings determined our choice of four biologic therapies (rituximab, abatacept, tocilizumab and anti-TNFα drugs) to consider for refractory JDM treatment when indicated and to evaluate for comparative effectiveness and safety in the future. Significance and Innovations This is the first report that provides a substantial clinical experience of a large group of pediatric rheumatologists with biologics for refractory JDM over five years. This experience with biologic therapies for refractory JDM may aid pediatric rheumatologists in the current treatment of these children and form a basis for further clinical research into the comparative effectiveness and safety of biologics for refractory JDM.


Assuntos
Dermatomiosite , Quimioterapia Combinada , Etanercepte/uso terapêutico , Glucocorticoides/uso terapêutico , Infliximab/uso terapêutico , Conduta do Tratamento Medicamentoso/tendências , Metotrexato/uso terapêutico , Rituximab/uso terapêutico , Antirreumáticos/uso terapêutico , Terapia Biológica/métodos , Criança , Dermatomiosite/epidemiologia , Dermatomiosite/terapia , Resistência à Doença , Quimioterapia Combinada/classificação , Quimioterapia Combinada/métodos , Quimioterapia Combinada/tendências , Feminino , Humanos , Masculino , Pediatria/métodos , Pediatria/tendências , Padrões de Prática Médica/estatística & dados numéricos , Inquéritos e Questionários , Estados Unidos/epidemiologia
2.
Int Arch Allergy Immunol ; 117(4): 239-43, 1998 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-10048895

RESUMO

Genetic predisposition and environmental factors modulate the expression of allergic phenotypes. The frequent allergic phenotype 'immediate cutaneous hypersensitivity' was established in mice as a model for atopy. Genetic dissection of this trait requires a robust procedure to assess the allergic phenotype. To this end, different mouse strains were immunized with birch pollen extract. Immediate cutaneous hypersensitivity reactions were induced through intradermal allergen exposure. Wheel formation was quantitated and expressed as a hypersensitivity score according to the bonitur method. This procedure identified A/J and C57BL/6 mice as high- and low-responder strains, respectively. Crosses of A/J and C57BL/6 mice should allow the characterization of mendelian factors responsible for the two extreme phenotypes identified here.


Assuntos
Dermatite Atópica/imunologia , Hipersensibilidade Imediata/diagnóstico , Hipersensibilidade Imediata/genética , Hipersensibilidade Imediata/imunologia , Alérgenos/imunologia , Animais , Modelos Animais de Doenças , Feminino , Predisposição Genética para Doença/imunologia , Imunização , Camundongos , Camundongos Endogâmicos A , Camundongos Endogâmicos AKR , Camundongos Endogâmicos C57BL , Fenótipo , Pólen/imunologia , Testes Cutâneos/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA